Live Investor Briefing – Prescient Therapeutics

Prescient Therapeutics (ASX: PTX)

Live Investor Briefing

Register for an Upcoming Webcast

Please join a special investor briefing with Prescient Therapeutics CEO and MD Steven Yatomi-Clarke.

In the session, Steven will discuss:

  • Why Prescient is positioned at the forefront of a current revolution within oncology, the largest sector in healthcare at US$280 billion.
  • How Prescient’s OmniCAR and CellPryme platforms can potentially enable and enhance cancer therapies as it moves from ‘treatment’ towards ‘personalised cure’.
  • How the company can address an ecosystem of many potential partners leading togreater upside and revenue opportunities and diversified commercial risk.
  • The ongoing progress of its targeted therapies, PTX-100 and PTX-200, through clinical studies and towards commercialisation.

This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.

Book Your Spot

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged to help manage our investor communications.


Steven Yatomi-Clarke (Speak feature)

Steven Yatomi Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.